한글목차

세계 재택 주입 요법 시장 규모는 2024년 454억 달러에 달했습니다. 향후 IMARC Group은 2033년에는 708억 달러에 달해 2025-2033년 5.1%의 연평균 성장률(CAGR)을 기록할 것으로 예상하고 있습니다. 노인 인구의 증가와 재택의료에 대한 선호도 증가가 시장을 주도하고 있습니다.

재택 주입 요법 시장 동향:

첨단 주입 기술 채택 증가

기술의 발전은 정확성, 안전성, 효율성을 향상시키는 스마트 주입 펌프와 안전 소프트웨어를 도입하여 재택 주입 요법을 강화하고 있습니다. 한편, 이러한 기술 혁신은 투약 오류를 줄이고, 더 나은 모니터링을 제공하며, 디지털 시스템과의 원활한 통합을 통해 환자의 재택 치료를 간소화하고 간병인의 부담을 덜어줍니다. 예를 들어, 박스터는 2024년 4월 대용량 주입 펌프 Novum IQ와 Dose IQ Safety Software의 미국 FDA 승인을 획득하여 통합형 스마트 펌프 솔루션을 제공함으로써 재택 주입 요법을 강화했습니다. 이 개발은 환자의 안전과 효율성을 향상시키고, 임상의의 업무량 문제를 해결하며, 커넥티드 케어를 발전시킬 수 있습니다.

전문 주입 서비스에 대한 수요 증가

만성질환에 대한 복잡한 치료를 필요로 하는 환자가 증가함에 따라 전문적인 주입 서비스의 필요성이 높아지고 있습니다. 또한, 이러한 서비스에서는 재택 환경에서 환자 맞춤형 치료가 제공되기 때문에 통원치료의 필요성이 감소합니다. 또한, 이러한 개별화된 접근 방식은 환자의 편안함과 치료 결과를 향상시키면서 장기적인 질병을 효과적으로 관리할 수 있도록 돕습니다. 예를 들어, 2024년 2월 다이나믹 액세스는 자가면역질환, 다발성 경화증 등 만성질환 환자에게 서비스를 제공하는 재택 주입 간호 전문 업체인 다이나믹 인퓨전(Dynamic Infusion)을 설립했습니다. 또한, 35개 이상의 전문 약국과 제휴하여 9개 주에서 연간 1만 건 이상의 가정 방문을 통해 환자 관리를 강화하고 있습니다.

디지털 헬스 툴 통합

재택 주입 요법에서 디지털 도구의 통합은 더 나은 환자 모니터링과 의료 제공자와 환자 간의 실시간 데이터 공유를 가능하게 합니다. 또한, 이러한 시스템은 치료 진행 상황을 파악하여 원격 치료 관리를 강화하고, 치료 순응도를 향상시키며, 치료 계획의 조정을 용이하게 하는 동시에 대면 진료의 필요성을 최소화할 수 있도록 돕습니다. 예를 들어, 2024년 5월, 무그는 가정 내 주입 요법 전용으로 설계된 CURLIN 8000 외래 주입 시스템의 미국 FDA 승인을 획득했습니다. 이 시스템은 정확한 다중 치료 주입과 직관적인 사용자 인터페이스를 제공하며, CURLIN RxManager와 통합하여 홈케어 약사와 환자의 안전과 통제력을 강화합니다.

목차

제1장 서문

제2장 조사 범위와 조사 방법

• 조사 목적
• 이해관계자
• 데이터 소스
  • 1차 정보
  • 2차 정보
• 시장 추정
  • 상향식 접근
  • 하향식 접근
• 예측 방법

제3장 주요 요약

제4장 소개

제5장 세계의 재택 주입 요법 시장

• 시장 개요
• 시장 실적
• COVID-19의 영향
• 시장 예측

제6장 시장 내역 : 제품별

• 주입 펌프
  • 주요 부문
    • 엘라스토머식
    • 전기기계식
    • 중력식
    • 기타
• 정맥내 세트
• IV 캐뉼라
• 니들리스 커넥터

제7장 시장 내역 : 용도별

• 항감염
• 내분비학
  • 주요 부문
    • 당뇨병
    • 기타
• 수분 보급 요법
  • 주요 부문
    • 운동선수
    • 기타
• 화학요법
• 경장영양
• 정맥영양
• 전문의약품
• 기타

제8장 시장 내역 : 지역별

• 북미
  • 미국
  • 캐나다
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주
  • 인도네시아
  • 기타
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 러시아
  • 기타
• 라틴아메리카
  • 브라질
  • 멕시코
  • 기타
• 중동 및 아프리카

제9장 SWOT 분석

제10장 밸류체인 분석

제11장 Porter's Five Forces 분석

제12장 가격 분석

제13장 경쟁 구도

• 시장 구조
• 주요 기업
• 주요 기업 개요
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Becton Dickinson and Company
  • Eli Lilly and Company
  • Fresenius SE & Co. KGaA
  • ICU Medical Inc.
  • JMS Co. Ltd.
  • Nipro Corporation
  • Option Care Health Inc.(Walgreen Co.)
  • Smiths Group plc
  • Terumo Corporation

영문목차

The global home infusion therapy market size reached USD 45.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 70.8 Billion by 2033, exhibiting a growth rate (CAGR) of 5.1% during 2025-2033. The growing elderly population, along with the increasing preference for home healthcare, is propelling the market.

Home Infusion Therapy Market Trends:

Increasing Adoption of Advanced Infusion Technology

Technological advancements are enhancing home infusion therapy by introducing smart infusion pumps and safety software that improve precision, safety, and efficiency. In contrast, these innovations help to reduce medication errors, offer better monitoring, and provide seamless integration with digital systems, thereby streamlining home-based care for patients and reducing the burden on caregivers. For instance, in April 2024, Baxter received U.S. FDA clearance for its Novum IQ large volume infusion pump and Dose IQ Safety Software, thereby enhancing home infusion therapy by offering integrated smart pump solutions. This development boosts patient safety and efficiency, addressing clinician workload challenges and advancing connected care.

Growing Demand for Specialized Infusion Services

The need for specialized infusion services has grown as more patients require complex treatments for chronic conditions. In addition, these services provide tailored therapies delivered in a home setting, thereby reducing the need for hospital visits. Furthermore, this personalized approach helps to manage long-term illnesses effectively while improving patient comfort and treatment outcomes. For instance, in February 2024, Dynamic Access launched dynamic infusion, a specialty home infusion nursing provider, which is serving patients with chronic conditions like autoimmune disorders and multiple sclerosis. Also, they partnered with 35+ specialty pharmacies, offering over 10,000 home visits annually across nine states, enhancing patient care.

Integration of Digital Health Tools

The integration of digital tools in home infusion therapy is enabling better patient monitoring and real-time data sharing between healthcare providers and patients. Moreover, these systems enhance remote care management by offering insights into therapy progress, thereby improving adherence and facilitating adjustments to treatment plans while minimizing the need for in-person consultations. For instance, in May 2024, Moog received U.S. FDA clearance for the CURLIN 8000 ambulatory infusion system, designed specifically for home infusion therapy. This system offers precise multi-therapy infusions and intuitive user interfaces and integrates with CURLIN RxManager, enhancing safety and control for home care pharmacists and patients.

Global Home Infusion Therapy Industry Segmentation:

Breakup by Product:

• Infusion Pumps
  • Elastomeric
  • Electromechanical
  • Gravity
  • Others
• Intravenous Sets
• IV Cannulas
• Needleless Connectors

Infusion pumps currently hold the largest home infusion therapy market demand

Infusion pumps exhibit a clear dominance in the market due to their precision in medication delivery, as they offer defined medication delivery and enhancing patient care. For example, Baxter launched its advanced Spectrum IQ pump, thereby improving patient safety and remote monitoring capabilities for home-based care.

Breakup by Application:

• Anti-Infective
• Endocrinology
  • Diabetes
  • Others
• Hydration Therapy
  • Athletes
  • Others
• Chemotherapy
• Enteral Nutrition
• Parenteral Nutrition
• Specialty Pharmaceuticals
• Others

Anti-infectives currently hold the largest home infusion therapy market statistics

Anti-infectives lead the market due to their increased use in treating severe infections, such as pneumonia, with intravenous antibiotics. For instance, Smiths Medical's CADD infusion system facilitates precise delivery and supports increased adoption.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America currently dominates the infusion therapy market revenue

The home infusion therapy market outlook has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

As per the home infusion therapy market overview, North America dominates the market, which is driven by advanced healthcare infrastructure and increasing demand for home-based treatments. Moreover, the region benefits from a growing elderly population and rising chronic disease cases, prompting more home infusion therapies. For example, CVS Health expanded its home infusion services, thereby enhancing access to these treatments across the U.S. Furthermore, high demand for at-home care, alongside supportive reimbursement policies and technological advancements, further strengthens the region's dominance in this market.

Competitive Landscape:

The home infusion therapy market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all market home infusion therapy companies have also been provided. Some of the key players in the market include:

• B. Braun Melsungen AG
• Baxter International Inc.
• Becton Dickinson and Company
• Eli Lilly and Company
• Fresenius SE & Co. KGaA
• ICU Medical Inc.
• JMS Co. Ltd.
• Nipro Corporation
• Option Care Health Inc. (Walgreen Co.)
• Smiths Group plc
• Terumo Corporation

Key Questions Answered in This Report:

• How has the global home infusion therapy market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global home infusion therapy market?
• What is the impact of each driver, restraint, and opportunity on the global home infusion therapy market growth?
• What are the key regional markets?
• Which countries represent the most attractive home infusion therapy market?
• What is the breakup of the market based on the product?
• Which is the most attractive product in the home infusion therapy market?
• What is the breakup of the market based on the application?
• Which is the most attractive application in the home infusion therapy market?
• What is the competitive structure of the global home infusion therapy market?
• Who are the key players/companies in the global home infusion therapy market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Home Infusion Therapy Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Infusion Pumps
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Elastomeric
    • 6.1.2.2 Electromechanical
    • 6.1.2.3 Gravity
    • 6.1.2.4 Others
  • 6.1.3 Market Forecast
• 6.2 Intravenous Sets
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 IV Cannulas
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Needleless Connectors
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Application

• 7.1 Anti-Infective
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Endocrinology
  • 7.2.1 Market Trends
  • 7.2.2 Key Segments
    • 7.2.2.1 Diabetes
    • 7.2.2.2 Others
  • 7.2.3 Market Forecast
• 7.3 Hydration Therapy
  • 7.3.1 Market Trends
  • 7.3.2 Key Segments
    • 7.3.2.1 Athletes
    • 7.3.2.2 Others
  • 7.3.3 Market Forecast
• 7.4 Chemotherapy
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Enteral Nutrition
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Parenteral Nutrition
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast
• 7.7 Specialty Pharmaceuticals
  • 7.7.1 Market Trends
  • 7.7.2 Market Forecast
• 7.8 Others
  • 7.8.1 Market Trends
  • 7.8.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia-Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 B. Braun Melsungen AG
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
  • 13.3.2 Baxter International Inc.
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
    • 13.3.2.3 Financials
    • 13.3.2.4 SWOT Analysis
  • 13.3.3 Becton Dickinson and Company
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 Financials
    • 13.3.3.4 SWOT Analysis
  • 13.3.4 Eli Lilly and Company
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
    • 13.3.4.4 SWOT Analysis
  • 13.3.5 Fresenius SE & Co. KGaA
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 Financials
    • 13.3.5.4 SWOT Analysis
  • 13.3.6 ICU Medical Inc.
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 Financials
    • 13.3.6.4 SWOT Analysis
  • 13.3.7 JMS Co. Ltd.
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
    • 13.3.7.3 Financials
  • 13.3.8 Nipro Corporation
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
    • 13.3.8.3 Financials
    • 13.3.8.4 SWOT Analysis
  • 13.3.9 Option Care Health Inc. (Walgreen Co.)
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
    • 13.3.9.3 Financials
    • 13.3.9.4 SWOT Analysis
  • 13.3.10 Smiths Group plc
    • 13.3.10.1 Company Overview
    • 13.3.10.2 Product Portfolio
    • 13.3.10.3 Financials
    • 13.3.10.4 SWOT Analysis
  • 13.3.11 Terumo Corporation
    • 13.3.11.1 Company Overview
    • 13.3.11.2 Product Portfolio
    • 13.3.11.3 Financials
    • 13.3.11.4 SWOT Analysis